This week, we read another article from the December 2022 issue of Medical Writing, this time discussing data sharing in pharma publications and how to make data sharing FAIRer. We hear about the upcoming launch of phase 2 of the NIH Preprint Pilot, about Nature’s new publication support for authors in low- and lower-middle-income countries, and about a new publication checklist from OASPA and UNESCO. We also read an interview with the artificial intelligence ChatGPT and get its thoughts on what impacts it might have on the research publishing world. Finally, we highlight upcoming talks about clinical trial reporting and data sharing, and we listen to a podcast discussing enhanced publication content.
To read:
Making data FAIRer via Medical Writing | 12-minute read
Sharing data is a cornerstone of the open science movement. Data sharing increases reusability, reduces waste, supports reproducibility and promotes innovation, while also promoting transparency and access to the latest information. While data sharing rates have increased in recent years, several obstacles remain that can inhibit data sharing best practice. Application of the FAIR principles – that is, making data findable, accessible, interoperable and reusable – can help overcome these obstacles. This article, written by Eniola Awodiya and Open Pharma’s very own Joana Osório, discusses FAIR data sharing in pharma publications and what can be done to make data sharing more FAIR in the future.
Phase 2 of the NIH Preprint Pilot launches later this month via National Institutes of Health National Library of Medicine | 2-minute read
Following on from our previous digest covering the NIH Preprint Pilot, the National Institutes of Health’s National Library of Medicine have now announced that phase 2 of the pilot will be launched at the end of January. The pilot will include all preprints funded by the NIH that have been posted to an eligible preprint server on or after 1 January 2023. You can read a full report on phase 1 of the preprint pilot here and find answers to any questions you may have by visiting this FAQ page.
Publishing support for LIC and LMIC authors via Springer Nature Group | 4-minute read
Researchers and authors from low-income countries are often prevented from publishing open access by prohibitively expensive article processing charges. To address this, Nature has announced that research from authors from over 70 low-income (LICs) or lower-middle-income countries (LMICs) can now be published open access in some Nature journals at no charge. These journals include Nature itself as well as Nature portfolio transformative journals such as Nature Chemistry. Fully open access titles such as Nature Communications and Scientific Reports are not included.
Have you made the list? A new publication checklist from OASPA and UNESCO via STM Publishing News | 2-minute read
The Open Access Scholarly Publishing Association (OASPA) and United Nations Educational, Scientific and Cultural Organization (UNESCO) have announced the launch of their joint Checklist for open access publishers on implementing the UNESCO Recommendation on Open Science. Developed as a part of UNESCO’s Open Science Toolkit, the checklist will provide guidelines to help publishers better implement open science policies.
An interview with ChatGPT via The Scholarly Kitchen | 20-minute read
At the end of 2022, the launch of ChatGPT made waves in the artificial intelligence (AI) community and beyond. The impressive and naturalistic nature of ChatGPT’s responses to posed questions, which are often indiscernible to those from a real human, have raised concerns in the research and publishing world about its potential to be used to generate scientific publications. In this article, Todd A Carpenter interviews ChatGPT to discuss what it knows about writing and publishing scholarly articles, if it thinks that there are ethical concerns about AI-written papers, and whether anything it writes can ever be truly novel.
To engage with:
The importance of clear and transparent clinical trial reporting via University of Oxford
Join Ruth Tunn (Research Fellow at NDORMS at the University of Oxford) on 30 January 2023 for her talk on Why does clear and transparent reporting of clinical trials matter to patients and the public? In this free hybrid event, organized by the NDORMS patient and public involvement group OPEN ARMS, Ruth will share why clear and transparent clinical trial reporting is important to patients and the public. The event will also provide an opportunity for patients and the general public to share and exchange research ideas with Ruth. Register for the event here.
The current and future landscape of data sharing via OASPA
Interested in recent developments in data sharing and what the future may hold? Then sign up to this free webinar hosted by Open Access Scholarly Publishing Association (OASPA) on 1 February 2023. Featuring data sharing experts Rachael Lammey (Crossref), Sarah Lippincott (ABB), Aravind Venkatesan (EMBL-EBI), Shelley Stall (AGU) and Kathleen Gregory (University of Vienna), this webinar will look to discuss why data sharing is important and what is being done to increase data sharing rates among authors. The webinar will also give the opportunity for you, the audience, to contribute your thoughts and opinions on data sharing. You can register for the webinar here!
To listen to:
Stay InformED on open science in 2023 via ISMPP | 15-minute listen
The first InformED podcast of 2023 by the International Society for Medical Publication Professionals (ISMPP) is now available to listen to! This first episode focuses on the advantages of enhanced publication content (EPC). Joining the InformED podcast this week is Neil Adams (Manager of Industry Solutions in North America at Karger Publishers), who discusses what the most common types of EPC are, which EPC provide the greatest value for both authors and readers, and the main obstacles preventing authors from using EPC. To listen to any of the InformED podcasts from 2022, you can click here!
Have you read the December 2022 issue of Medical Writing about Open Science and Open Pharma? Read the full issue here!
